Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma

M Costacurta; SJ Vervoort; SJ Hogg; BP Martin; RW Johnstone; J Shortt

Journal article

Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma

M Costacurta, SJ Vervoort, SJ Hogg, BP Martin, RW Johnstone, J Shortt

Haematologica | FERRATA STORTI FOUNDATION | Published : 2021

DOI: 10.3324/haematol.2020.265611

Abstract

Not available.

University of Melbourne Researchers

Stephanus Vervoort Author

Ricky Johnstone Author

Jake Shortt Author

Related Projects (1)

MOLECULAR & TRANSLATIONAL CHARACTERISATION OF IMID-MEDIATED BET-PROTEIN DEGRADATION IN MULTIPLE MYELOMA

Thalidomide-like drugs (called IMiDs) are an essential treatment for multiple myeloma, a common incurable blood cancer. We have discovered t..

Grants

Awarded by Cancer Council Victoria

Funding Acknowledgements

JS is supported by an Australian Medical Research Future Fund Next Generation Clinician Researcher Fellowship; this research was funded by NHMRC project Ggrant 1127387; RWJ was supported by the Cancer Council Victoria, National Health and Medical Research Council of Australia (NHMRC), and The Kids' Cancer Project; The Victorian Center for Functional Gnomics, the Molecular Genomics Core and the Flow Cytometry Core Facilities at the Peter MacCallum Cancer Center provided excellent technical support; The Peter MacCallum Foundation and Australian Cancer Research Foundation provide generous support for equipment and core facilities.